Cartesian Therapeutics Cash, Cash Equivalents, And Restricted Cash Of $88.9M And Net Proceeds From $130M Pipe Financing Are Expected To Support Development Of Descartes-08 In Myasthenia Gravis; End-of-phase 2 Meeting With FDA Expected By Year-end
Cartesian Therapeutics Cash, Cash Equivalents, And Restricted Cash Of $88.9M And Net Proceeds From $130M Pipe Financing Are Expected To Support Development Of Descartes-08 In Myasthenia Gravis; End-of-phase 2 Meeting With FDA Expected By Year-end
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.